Affordable Access

Sildenafil: a new oral therapy for erectile dysfunction.

Authors
  • Noss, M B1
  • Christ, G J
  • Melman, A
  • 1 Department of Urology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York 10467, USA.
Type
Published Article
Journal
Drugs of today (Barcelona, Spain : 1998)
Publication Date
March 1999
Volume
35
Issue
3
Pages
211–217
Identifiers
PMID: 12973386
Source
Medline
License
Unknown

Abstract

Sildenafil citrate (Viagra) is a relatively selective 5-phosphodiesterase (PDE) inhibitor. It is the first oral medication approved for the treatment of erectile dysfunction (ED). The neuronal release of NO which binds to the heme-containing region of guanylate cyclase increases levels of cGMP. This leads to a cascade of reaction which results in corporal smooth muscle relaxation and penile erection. Sildenafil causes an erection by inhibiting PDE5, which in turn causes an increase in the intracellular levels of cGMP. Sildenafil is well absorbed after a single oral administration with a t(1/2) of approximately 4 h. The mode of onset varies from 0.5-4 h. The drug has been used in millions of men since first approved by the U.S. FDA 1 year ago and has revolutionized the approach to, and therapy of, erectile dysfunction.

Report this publication

Statistics

Seen <100 times